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A B S T R A C T
Background
Colloid solutions are widely used in fluid resuscitation of critically ill patients. There are several choices of colloid and there is ongoing
debate about the relative effectiveness of colloids compared to crystalloid fluids.
Objectives
To assess the effects on mortality of colloids compared to crystalloids for fluid resuscitation in critically ill patients.
Search strategy
We searched the Injuries Group specialised register, Cochrane Controlled Trials Register, MEDLINE, EMBASE and BIDS Index to
Scientific and Technical Proceedings, and checked reference lists of trials and review articles.
Selection criteria
All randomised and quasi-randomised trials of colloids compared to crystalloids, in patients requiring volume replacement. Cross-over
trials and trials in pregnant women and neonates were excluded.
Data collection and analysis
Two reviewers independently extracted data and rated quality of allocation concealment. Trials with a ’double-intervention’, such as
those comparing colloid in hypertonic crystalloid to isotonic crystalloid, were analysed separately. The analysis was stratified according
to colloid type and quality of allocation concealment.
Main results
Colloids compared to crystalloids
Albumin or plasma protein fraction. Nineteen trials reported data on mortality, including a total of 7576 patients. The pooled relative
risk (RR) from these trials was 1.02 (95% confidence interval [95% CI] 0.93 to 1.11). When the trial with poor quality allocation
concealment was excluded, pooled RR was 1.01 (95% CI 0.92 to 1.10).
Hydroxyethyl starch. Ten trials compared hydroxyethyl starch with crystalloids, including a total of 374 randomised participants. The
pooled RR was 1.16 (95% CI 0.68 to 1.96).
Modified gelatin. Seven trials compared modified gelatin with crystalloid, including a total of 346 randomised participants. The pooled
RR was 0.54 (95% CI 0.16 to 1.85).
Dextran. Nine trials compared dextran with a crystalloid, including a total of 834 randomised participants. The pooled relative risk
was RR 1.24 (95% CI 0.94 to 1.65).
Colloids in hypertonic crystalloid compared to isotonic crystalloid
Eight trials compared dextran in hypertonic crystalloid with isotonic crystalloid, including 1283 randomised participants. Pooled RR
was 0.88 (95% CI 0.74 to 1.05).
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Authors’ conclusions
There is no evidence from randomised controlled trials that resuscitationwith colloids reduces the risk of death, compared to resuscitation
with crystalloids, in patients with trauma, burns or following surgery. As colloids are not associated with an improvement in survival,
and as they are more expensive than crystalloids, it is hard to see how their continued use in these patients can be justified outside the
context of randomised controlled trials.
P L A I N L A N G U A G E S U M M A R Y
No evidence that colloids are more effective than crystalloids in reducing mortality in people who are critically ill or injured
Trauma, burns or surgery can cause people to lose large amounts of blood. Fluid replacement, giving fluids intravenously (into a vein)
to replace lost blood, is used to try to maintain blood pressure and reduce the risk of dying. Blood products, non-blood products
or combinations are used, including colloid or crystalloid solutions. Colloids are increasingly used but they are more expensive than
crystalloids. The review of trials found no evidence that colloids reduce the risk of dying compared with crystalloids.
B A C K G R O U N D
Fluid resuscitation for hypovolaemia is a mainstay of the med-
ical management of critically ill patients, whether as a result of
trauma, burns, major surgery or sepsis. Although recent studies
(Bickell 1994) have suggested that the timing of volume replace-
ment deserves careful consideration, when it comes to selecting
the resuscitation fluid clinicians are faced with a range of options.
At one level the choice is between a colloid or crystalloid solution.
Colloids are widely used, having been recommended in a num-
ber of resuscitation guidelines and intensive care management al-
gorithms (Vermeulen 1995; Armstrong 1994). The US Hospi-
tal Consortium Guidelines recommend that colloids are used in
haemorrhagic shock prior to the availability of blood products,
and in non-haemorrhagic shock following an initial crystalloid in-
fusion. A 1995 survey of US academic health centres, however,
found that the use of colloids far exceeded even the Hospital Con-
sortium recommendations (Yim 1995). Surveys of burn care in
the US (Fakhry 1995) and in Australia (Victorian DUAC 1991)
found that the use of colloids for resuscitation varied without a
set pattern. The choice of fluid has considerable cost implications.
Volume replacement with colloids is considerably more expensive
than with crystalloids. Clinical studies have shown that colloids
and crystalloids have different effects on a range of important phys-
iological parameters. Because of these differences, all-cause mor-
tality is arguably the most clinically relevant outcome measure in
randomised trials comparing the two fluid types. Although there
have been previous meta-analyses of mortality in randomised tri-
als comparing colloids and crystalloids (Velanovich 1989, Bisonni
1991), neither of these satisfy the criteria that have been proposed
for scientific overviews (Oxman 1994), and they predate most of
the trials that have been conducted using synthetic colloids, and
hypertonic crystalloid solutions. The purpose of this review is to
identify and synthesise all available unconfounded evidence of the
effect on mortality in critically ill patients of colloids compared to
crystalloids for volume replacement.
O B J E C T I V E S
To determine the effects on mortality of using colloids compared
to crystalloids, during fluid resuscitation in critically ill patients.
C R I T E R I A F O R C O N S I D E R I N G
S T U D I E S F O R T H I S R E V I E W
Types of studies
Controlled trials in which participants were randomised to treat-
ment groups (colloid or control) on the basis of random or quasi-
random allocation. As the comparison between fluid type was in
terms of effects on mortality, randomised cross-over trials were
excluded.
Types of participants
Critically ill patients (excluding neonates) who required volume
replacement. Types of participants included were those who were
critically ill as a result of trauma, burns, were undergoing surgery,
or had other critical conditions such as complications of sepsis.
Preoperative elective surgical patients were excluded.
Types of intervention
The colloids considered were Dextran 70, hydroxyethyl starches,
modified gelatins, albumin or plasma protein fraction.
There is overlap between albumin given for volume replacement
and albumin given as a nutritional supplement, andmany patients
with a critical illness have low serum albumin. Where the trial
was of total parenteral nutrition with or without albumin, it was
excluded. We included trials where the albumin was given as part
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of volume replacement guided by colloid osmotic pressure or al-
bumin levels.
The control group received crystalloid (isotonic or hypertonic) for
fluid replacement. Trials where both groups received blood were
included.
Trials of fluids used for other purposes were excluded. For example,
trials of pre-loading in preparation for elective surgery, and trials in
patients undergoing fluid loading before cardiopulmonary bypass,
were excluded.
Types of outcome measures
The principal outcome measure was mortality from all causes,
assessed at the end of the follow-up period scheduled for each trial.
S E A R C H M E T H O D S F O R
I D E N T I F I C A T I O N O F S T U D I E S
See: methods used in reviews.
MEDLINE: latest search, September 2002.
#1 colloid*
#2 albumin*
#3 ppf
#4 dextran
#5 gelatin*
#6 gentran*
#7 haemaccel*
#8 hemaccel*
#9 pentastarch
#10 pentaspan
#11 hetastarch
#12 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or
#11
#13 crystalloid*
#14 ringer*
#15 hartman*
#16 sodium*
#17 potassium*
#18 salin*
#19 #13 or #14 or #15 or #16 or #17 or #18
#20 fluid
#21 therapy
#22 fluid near2 therapy
#23 volume
#24 restor*
#25 volume near2 restor*
#26 fluid
#27 resuscit*
#28 restor*
#29 therap*
#30 fluid near2 (resuscit* or restor* or therap*)
#31 plasma
#32 substit*
#33 fluid
#34 volume
#35 substit*
#36 replace*
#37 (plasma near2 substit*) or ((fluid or volume) near2 (substit*
or replace*))
#38 #22 or #25 or #30 or #37
#39 #12 and #19 and #38
#40 controlled
#41 clinical
#42 trial*
#43 controlled clinical trial*
#44 randomi*
#45 controlled
#46 trial*
#47 randomi* controlled trial*
#48 explode research design/ all subheadings
#49 double
#50 blind
#51 double blind
#52 meta
#53 analysis
#54 metaanalysis
#55 meta analysis or metaanalysis
#56 clinical trial in pt
#57 #43 or #47 or #48 or #51 or #55 or #56
#58 #39 and #57
The reference lists of all identified trials and review articles were
checked, and we contacted the trialists, to ask if any studies had
been missed.
The update of the Injuries Group review on Human albumin
(Albumin 2004) also found new papers that were relevant for
this review. The major SAFE trial (SAFE 2004) was published
after the search was done but, the reviewers being aware of its
publication, it was also considered and was found to meet the
inclusion criteria.
Full details of the search strategies used can be obtained from the
Injuries Group Trials Search Co-ordinator.
M E T H O D S O F T H E R E V I E W
Allocation concealment was scored as described by Schulz (Schulz
1995). In particular, the presence of solutions in identical
containers was only taken to mean adequate concealment if the
fluid containers were used sequentially.
Information on blinding and loss to follow-up was collected but
not scored.
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As a result of comments on the previous version of this review,
trials were stratified by type of fluid rather than type of original
injury.
Relative risk (RRs) and 95% confidence interval (95% CI)
were calculated for each study using a fixed effects model.
Each comparison was then inspected visually for evidence of
heterogeneity and a chi-squared test performed. If there was no
evidence of heterogeneity (visually or with a p value < 0.1) the
trials were pooled within each type of fluid, but not combined
between type of fluid.
Trials with allocation concealment judged as inadequate were then
excluded and the calculations repeated.
D E S C R I P T I O N O F S T U D I E S
There were 53 trialsmeeting the inclusion criteria for study design,
participants and interventions. We were able to obtain data on
deaths for 46 of these. Details of the remaining trials are also
reported in the Table of Included Studies for completeness.
Reasons for exclusion of trials were: the use of a cross-over design,
testing a resuscitation algorithm, giving the control group oral
fluids, the interventionbeingdirected to themaintenance of serum
albumin levels, for haemodilution, for fluid loading and for the
reduction of intracranial pressure (see Table of Excluded Studies).
Of the 46 randomised controlled trials with data on deaths, the
quality of allocation concealment was adequate in six trials and
unclear in most of the others.
There were 42 comparisons of colloids and crystalloids (add-on
colloid), nine comparisons of colloid inhypertonic crystalloidwith
isotonic crystalloid, and three comparisons of colloid with hyper-
tonic crystalloid (see Table of Included Studies).
M E T H O D O L O G I C A L Q U A L I T Y
In general, the design of studies was not well reported. This is
reflected in the number of unclear scores given for allocation con-
cealment. We also collected information on blinding and loss to
follow-up. Blinding was not well reported and loss to follow-up
was generally small. The characteristics for each trial are listed in
the Table of Included studies.
R E S U L T S
Colloids compared to crystalloids
Albumin or plasma protein fraction
Twenty trials reported data on mortality, including a total of 7576
patients. The pooled RR from these trials was 1.02 (95% CI 0.93
to 1.11). When the one trial with poor quality allocation conceal-
ment (Lucas 1978) was excluded, the pooled RR was 1.01 (95%
CI 0.92 to 1.01).
Hydroxyethyl starch
Ten trials compared hydroxyethyl starch with crystalloids, includ-
ing a total of 374 randomised participants. The pooled RR was
1.16 (95% CI 0.68 to 1.96).
Modified gelatin
Seven trials compared modified gelatin with crystalloid, including
a total of 346 randomised participants. The pooled RR was 0.54
(95% CI 0.16 to 1.85).
Dextran
Nine trials compared dextran with a crystalloid, including a total
of 834 randomised participants. The pooled RR was 1.24 (95%
CI 0.94 to 1.65).
Colloids in hypertonic crystalloid compared to isotonic crys-
talloid
One trial compared albumin and hypertonic saline with isotonic
crystalloid. Its relative risk of death was 0.50 (0.06 to 4.33).
Eight trials compared dextran in hypertonic crystalloid with iso-
tonic crystalloid, including 1283 randomised participants. The
pooled RR was 0.88 (0.74 to 1.05).
Colloids in isotonic crystalloid compared to hypertonic crys-
talloid
Three trials compared colloids in isotonic crystalloid with hyper-
tonic crystalloid. In two of these, where the colloid was either
gelatin or starch, there were no deaths in either group. In the re-
maining trial, with 38 participants, there was a relative risk of
death of 7.00 (0.39 to 126.93) for use of colloid, based on three
deaths in the treatment group and none in the control group.
D I S C U S S I O N
This systematic review synthesises the evidence from randomised
controlled trials comparing colloid and crystalloid fluid resuscita-
tion across a wide variety of clinical conditions. The review has
been updated and extensively revised to take into account the com-
ments made since it was first published. In particular, several com-
mentators pointed out that it is inappropriate to combine effect
estimates from studies of different colloids. For example, it was
argued that large molecular weight colloids such as hydroxyethyl
starch may be better retained in the vascular compartment than
albumin and gelatins, and would therefore be more likely to show
a favourable effect on mortality (Gosling 1998). In response to
these concerns, the review has been stratified by type of colloid.
However, the pooled relative risks fail to show a mortality benefit
for resuscitation with any type of colloid.
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There was a trend towards a favourable effect on mortality for col-
loids in hypertonic crystalloid, compared to isotonic crystalloids.
Nevertheless, the results are compatible with the play of chance.
Common to all meta-analyses, this systematic review may have in-
cluded studies whose interventions and patient characteristics are
sufficiently incomparable that the calculation of a summary effect
measure may be questioned. The resuscitation regimen differed
between trials. Some trials randomised participants to an initial
quantity of colloid or crystalloid, and then proceeded with some
form of standard resuscitation for all participants. Other trials re-
suscitated with the allocated fluid to pre-determined end-points,
either resuscitation end-points, or in the case of trauma, until cor-
rective surgery. In addition, the type of colloid or crystalloid, the
concentration, and the protocol to determine the quantity of fluid
varied. Despite these differences, all participants were in need of
volume replacement, and we believe that this variation in the in-
tervention would have an impact on the size of the effect, rather
than on its direction.
As regards the effects of albumin versus crystalloid, most of the
information (as indicated by the weighting in the meta-analysis)
was provided by the SAFE trial. The SAFE trial used central ran-
domisation with a minimisation algorithm to ensure balance on
known potential confounders. Blinding was assured through the
use of specially designed masking cartons and specially designed
and manufactured administration sets. The authors report that
the effectiveness of the blinding was confirmed in a formal study
before the trial was initiated. In brief, this was a well- conducted,
high-quality trial. There were 726 deaths (20.9%) in the albumin-
treated group and 729 deaths (21.1%) in the saline-treated group
(RR of death 0.99; 95%CI 0.91 to 1.09). Although even this large
trial was unable to confirm or refute the possibility of a modest
benefit or harm from albumin, it has provided some reassurance
that any hazard from albumin, if indeed there is any, is unlikely to
be as extreme as was suggested by the results from the previously
published (now here updated) meta-analysis of much smaller tri-
als. The pooled relative risk for death with albumin in this updated
meta-analysis is now 1.02 (0.93 to 1.11). It is important to note
that the effect estimate from the SAFE trial is entirely consistent
with the results of previous trials of albumin in hypovolaemia and
there is no significant heterogeneity (I2 =0%, p=0.46).
The results of this updated meta-analysis have important policy
implications. There is still no evidence that colloids are superior to
crystalloids as a treatment for intravascular volume resuscitation in
critically ill patients. Importantly, the SAFE trial also provided no
evidence of any other clinical advantages from using albumin. It
also debunked the belief, from pathophysiological inference, that
very large volumes of crystalloid must be administered to reach
the same resuscitation end-points as can be achieved using much
smaller volumes of colloid. In the SAFE trial, the ratio of albu-
min administered to saline administered was approximately 1:1.4.
Colloids, in particular albumin, are considerably more expensive
than crystalloids, and albumin is a blood product and so carries
at least a theoretical infectious disease risk. The economic oppor-
tunity cost of on-going colloid use, particularly albumin use, is
likely to be considerable and for this reason its on-going use in
this context is unjustified.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is no evidence from randomised controlled trials that re-
suscitation with colloids, instead of crystalloids, reduces the risk
of death in patients with trauma, burns or following surgery. As
colloids are not associated with an improvement in survival, and
further, colloids are considerably more expensive than crystalloids,
it is hard to see how their continued use outside the context of
randomised controlled trials in subsets of patients of particular
concern, can be justified.
Implications for research
Future trials may need to concentrate on specific sub-groups of
patients to identify people who may benefit from colloids rather
than crystalloids.
P O T E N T I A L C O N F L I C T O F
I N T E R E S T
None known.
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T A B L E S
Characteristics of included studies
Study Boldt 1986
Methods Randomised controlled trial, using sealed opaque envelopes.
Information on allocation concealment was obtained on contact with the authors.
Blinding and loss to follow-up not mentioned.
Participants 55 patients undergoing elective aorto-coronary bypass surgery.
Exclusion criteria were ejection fraction < 50% and LVEDP > 15 mmHg.
Interventions 1) 300ml 20% human albumin solution (n=15).
2) 500ml 3% hydroxyethylstarch (n=13).
3) 500ml 3.5% gelatine (n= 14).
4) No colloid (n=13).
Outcomes Haemodynamic variables were measured.
Deaths not reported.
Notes Follow-up until discharge from intensive care.
Allocation concealment B – Unclear
Study Boldt 1993
Methods Randomised controlled trial.
Allocation concealment by sealed opaque envelopes (information from author).
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Characteristics of included studies (Continued )
Blinding and loss to follow-up not mentioned.
Participants 75 men undergoing elective aortocoronary bypass grafting, who had a pulmonary capillary wedge pressure
of less than 5 mmHg after induction of anaesthesia.
Interventions 1) 5% albumin (n=15).
2) 6% HES, mean molecular weight 450,000 (n=15).
3) 6% HES, mean molecular weight 200,000 (n=15).
4) 3.5% gelatin (n=15).
5) No colloid (n=15).
Fluid used through operation and on intensive care post-op.
Outcomes Deaths not reported, author confirmed there were no deaths.
Notes Follow-up to 1 day.
Allocation concealment B – Unclear
Study Boldt 2001
Methods Randomised controlled trial, using a closed-envelope system.
Participants 100 patients undergoing major abdominal surgery.
Interventions 1) Ringer’s lactate (n=25).
2) 6% HES, mean molecular weight 200kDa, degree of substitution 0.5 (n=25).
3) 6% HES, mean molecular weight 130kDa, degree of substitution 0.4 (n=25).
4) 4% modified fluid gelatin, molecular weight 35kDA (n=25).
Outcomes Deaths.
Orthostatic problems.
Haemodynamics and laboratory data.
Fluid input and output.
Costs.
Notes Follow-up period unclear.
Allocation concealment B – Unclear
Study Boutros 1979
Methods Randomised controlled trial (“randomly divided”).
Method of allocation concealment not described.
Blinding not mentioned.
No loss to follow-up.
Participants 24 people undergoing major operative procedures on the abdominal aorta.
Interventions 1) Albumin in 5% dextrose (n=7).
2) 5% dextrose and Ringer’s lactate (n=8).
3) 5% dextrose in 0.45% saline (n=9).
Allocated fluids were used on admission to ICU, following surgery, guided by PAWP.Whole blood also given
if clinically needed.
Outcomes Deaths reported.
Notes Follow-up to discharge from hospital.
Allocation concealment B – Unclear
Study Bowser-Wallace 1986
Methods Quasi-randomised controlled trial (allocation by alternation).
Blinding not mentioned.
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Characteristics of included studies (Continued )
No loss to follow-up.
Participants Admitted for burns of 30% or more.
Age range 5 months to 21 years.
Excluded if already given more than half calculated daily requirement before reaching hospital.
Interventions 1) 2ml/kg/%burnRinger’s lactate over 24 hrs, then 0.5ml plasmanate/kg/%burn over 24 hrs plus 5%dextrose
(n=19).
2) 2ml/kg/%burn hypertonic lactated saline over 24 hrs, then 0.6ml/kg/%burn hypertonic lactated saline
over 24 hrs plus oral Haldane’s solution. (n=19)
IV fluids stopped at 48 hrs (n=19).
Outcomes Deaths reported.
Fluid and electrolytes given, weight, haematocrit.
Notes Follow-up to 5 days.
Allocation concealment C – Inadequate
Study Chavez-Negrete 1991
Methods Randomised controlled trial (allocation by ”random“) numbers”).
Blinding not mentioned.
No loss to follow-up.
Participants Adults admitted to an emergency room with acute gastrointestinal haemorrhage, systolic blood pressure 90
mmHg or less for up to 1 hr and normal electrocardiograph.
Excluded if pregnant or had renal, cardiac or neurological disease.
Interventions 1) Initial infusion of 250ml 7.5% saline/6% Dextran 60 given IV (16 patients) or intraosseous (n=10).
2) Initial IV infusion of 250ml Ringer’s lactate. (n=23)
Resuscitation continued with red cells, 0.9% saline and Dextran 40 according to clinical judgement.
Outcomes Death.
Haemodynamic variables.
Notes Follow-up to 24 hours.
Allocation concealment B – Unclear
Study Dawidson 1991
Methods Randomised controlled trial (allocation by drawing a card from a deck).
Blinding not mentioned.
No loss to follow-up.
Participants Adults undergoing elective abdominal aortic surgery.
No exclusions mentioned.
Interventions 1)3% Dextran 70 in Ringer’s lactate. (n=10)
2) IV Ringer’s lactate. (n=10)
Fluid used during and for 24 hrs after operation, guided by haemodynamic variables.
Outcomes Death.
Volume transfused, weight change, haemodynamic variables.
Notes Follow-up to discharge from hospital.
Allocation concealment C – Inadequate
Study Dehne 2001
Methods Randomised controlled trial; allocation by sealed envelope assignment.
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Characteristics of included studies (Continued )
Participants 60 male patients (of American Society of Anesthesiologists physical status 1 or 2) scheduled for middle ear
surgery.
Interventions 1) Lactated Ringer’s solution (n=15).
2) 6% HES: molecular weight 200kD, degree of substitiution 0.5 (n=15).
3) 6% HES: molecular weight 200kD, degree of substitiution 0.60-0.66 (n=15).
4) 6% HES: molecular weight 450kD, degree of substitiution 0.7 (n=15).
Outcomes Deaths not stated but ’all’ patients discharged 10-14 days after surgery; therefore no deaths.
Central venous pressure.
Urine output.
Blood osmolality.
Urine osmolality.
Notes Follow-up two days.
Allocation concealment B – Unclear
Study Eleftheriadis 1995
Methods Patients “randomizedly distributed”.
Blinding not mentioned.
Unable to assess loss to follow-up.
Participants Participants were undergoing coronary artery bypass surgery.
Interventions 1) 6% hydroxyethylstarch.
2) 3.5% gelatine.
3) Ringer’s lactate
Allocated fluid was used in the post-operative period only guided by mean arterial pressure.
Outcomes Deaths were not reported.
Haemodynamic variables.
Notes Follow-up period unspecified.
Allocation concealment B – Unclear
Study Ernest 1999
Methods Randomised controlled trial, allocation concealment not described.
No blinding.
No loss to follow-up mentioned.
Participants Patients with a clinical diagnosis of sepsis.
Interventions 1) 5% albumin (n=9).
2) 0.9% saline (n=9).
Volume of infusion guided by PAWP.
Outcomes Haemodynamic variables and volume measurements.
Deaths not reported.
Notes Follow-up to immediately after infusion.
Allocation concealment B – Unclear
Study Evans 1996
Methods Quasi-randomised trial (allocation by day of the week).
Blinding not mentioned.
No loss to follow-up.
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Characteristics of included studies (Continued )
Participants Aged 16 or more, admitted with trauma to an emergency centre within 2 hours after injury, only crystalloid
as a pre-hospital infusion.
Excluded if had underlying illness likely to affect clotting.
Interventions 1) IV haemaccel (n=11).
2) IV Ringer’s lactate (n=14).
Fluid was used until vital signs were stable.
Outcomes Deaths from author.
Clotting variables.
Notes Follow-up period unspecified.
Allocation concealment C – Inadequate
Study Gallagher 1985
Methods Randomised controlled trial. Method of allocation concealment not described. Author contacted - allocation
concealment by computerised system - patient details were entered before treatment assignment was revealed.
Blinding not mentioned.
No loss to follow-up.
Participants Patients after coronary artery bypass graft surgery.
Exclusions: patients with significant left main coronary artery stenosis, poor left ventricular function or poor
pulmonary function.
Interventions 1) IV 5% albumin (n=5).
2) IV 6% hydroxyethylstarch (n=5)
3) IV Ringer’s lactate (n=5).
Fluid used from admission to intensive care post op, guided by PAWP. RBC given if needed.
Five patients received 5% albumin. Five patients received lactated Ringer’s.
Outcomes Deaths were not reported. Author contacted and confirmed that there were no deaths in any group.
Haemodynamic data.
Notes Follow-up to 1 day.
Allocation concealment A – Adequate
Study Goodwin 1983
Methods Randomised controlled trial - assigned by ’random numbers table’.
Method of allocation concealment unclear.
Blinding not mentioned.
No loss to follow-up.
Participants 79 previously healthy young adults admitted with burns.
No exclusion criteria reported.
Interventions 1) 2.5% albumin in Ringer’s lactate (n=40).
2) Ringer’s lactate (n=39).
Fluids on day 1 guided by haemodynamic variable. On day 2, given at 0.3-0.5ml/kg/%burn, then 5%
dextrose.
Outcomes Deaths reported.
Lung water in some.
Infections.
Notes Follow-up to discharge from hospital.
Allocation concealment B – Unclear
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Study Grundmann 1982
Methods Randomised controlled trial.
Method of allocation concealment unclear.
Blinding not mentioned.
No loss to follow-up.
Participants 20 people undergoing partial gastrectomy.
The average age was 50 years (range 19-84).
No exclusion criteria reported.
Interventions 1) Colloid group received human albumin solution. (n=14).
2) Details of crystalloid were not reported. (n=6).
Allocated fluid was continued for 4 days after operation.
Outcomes Deaths reported.
Volumes of fluid given.
Haemodynamic variables.
Notes Follow-up to discharge from hospital.
Allocation concealment B – Unclear
Study Hall 1978
Methods Quasi-randomised controlled trial (participants were stratified by age, extent of burn and aetiology, and then
allocated by alternation).
Blinding not mentioned.
No loss to follow-up.
Participants Burns covering more than 10% of the body surface (for children), and more than 15% of the body surface
(for adults).
No exclusions mentioned.
Interventions 1) 120ml/%burn IV 6% Dextran 70 in 0.9% saline over 48 hrs plus oral water or IV 5% dextrose for
’metabolic requirements’ (n=86).
2) 4ml/kg/%burn IV Ringer’s lactate over 24 hrs, then 10% of initial body weight of fluid over 24 hrs plus
oral water (n=86).
Outcomes Death.
Fluid given, haemodynamic variables.
Notes Follow-up to discharge from hospital.
Allocation concealment C – Inadequate
Study Hartmann 1993
Methods Randomised controlled trial (method of allocation unclear).
Blinding not mentioned.
No loss to Follow-up.
Participants Adults undergoing major abdominal surgery.
Exclusions: cardiorespiratory dysfunction, uraemia, diabetes, taking steroids, anticoagulants or diuretics.
Interventions 1) IV Dextran 70 in saline (concentration not given) with 2.5% dextrose. (n=15).
2) IV saline (concentration not given) with 2.5% dextrose. (n=14).
Both groups given red cells, plasma, Dextran 70 and crystalloids during the operation as decided by the
clinician. Post-operative fluids according to the trial group guided by tissue oxygen tension to the end of
resuscitation.
Outcomes Death not reported.
Fluid given, haemodynamic variables.
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Notes Follow-up to 7 days.
Allocation concealment B – Unclear
Study Jelenko 1978
Methods Randomised controlled trial, method of allocation concealment unclear.
Blinding not mentioned.
No loss to follow-up.
Participants 19 people with burns covering more than 20% of body surface.
Interventions 1) 12.5% albumin in hypertonic saline (240MeQ Na+, 120 MeQ chloride, 120 MeQ lactate), (n=7).
2) Hypertonic saline (240MeQ Na+, 120 MeQ chloride, 120 MeQ lactate). (n=5).
3) Ringer’s lactate (n=7).
Allocated fluid was used, guided by haemodynamic variables, to the end of resuscitation.
Outcomes Deaths reported.
Haemodynamic variables.
Notes Follow-up to end of resuscitation.
Allocation concealment B – Unclear
Study Karanko 1987
Methods Randomised controlled trial. Description of allocation procedure unclear.
Blinding not mentioned.
No loss to follow-up.
Participants 32 adult men scheduled for coronary artery bypass surgery.
Exclusions: left ventricular ejection fraction under 40%, abnormal lung function.
Interventions 1) Colloid group received 6% dextran 70 (n=14).
2) Ringer’s lactate (n=18).
Allocated fluid was used to the end of resuscitation.
Outcomes Deaths reported.
Haemodynamic variables.
Lung water.
Notes Follow-up 2 weeks.
Allocation concealment B – Unclear
Study Lang 2001
Methods Randomised controlled trial, using a closed-envelope system.
Participants 42 patients scheduled for elective major abdominal surgery.
Interventions 1) Lactated Ringer’s (n=21).
2) 6% HES, molecular weight 139kD, degree of substitution 0.4 (n=21).
Outcomes Deaths.
Haemodynamics and laboratory data.
Tissue oxygenation.
Voume input and output.
Notes Follow-up period unclear.
Allocation concealment A – Adequate
Study Ley 1990
Methods Randomised controlled trial.
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Method of allocation concealment unclear.
Assessment of chest x-ray blinded.
No loss to follow-up.
Participants 21 people undergoing coronary artery bypass grafting or valve surgery.
Interventions 1) 6% hetastarch up to 1.5L then 5% plasma protein fraction (n=11).
2) 0.9% saline (n=10).
Allocated fluid was used for post-operative fluid resuscitation.
Outcomes Deaths were not reported.
Pulmonary and peripheral oedema.
Haemodynamic variables.
Notes Follow-up to discharge.
Allocation concealment B – Unclear
Study Lowe 1977
Methods Randomised controlled trial, allocation by sealed envelopes.
Blinding not mentioned.
No loss to follow-up.
Participants Participants with serious trauma.
Interventions 1) 25% albumin in Ringer’s lactate (n=77).
2) Ringer’s lactate (n=94).
Allocated fluid was used throughout the pre- and intra-operative period.
Outcomes Deaths reported.
Notes Follow-up to 5 days post-operatively. Data on the 30 participants with chest injuries who were left out of
the Lowe 1977 report, but included in Moss 1981, have been included in the meta-analysis.
Allocation concealment B – Unclear
Study Lucas 1978
Methods Randomised controlled trial.
Randomisation was based on the last digit of each patient’s case number.
Participants 52 seriously injured patients.
Interventions 1) Standard resuscitation regimen (’balanced electrolyte’, blood, fresh frozen plasma) plus salt poor albumin,
maximum 150g during surgery and 150g per day for the next 5 days (n=27).
2) Standard resuscitation regimen as above (n=25).
Outcomes Deaths reported in some patients.
Notes In the final report of 94 randomised patients deaths were not reported. However, in this preliminary report
of 52 injured patients deaths were reported.
Allocation concealment C – Inadequate
Study Mattox 1991
Methods Quasi-randomised, allocation by alternation.
Double-blind.
2 patients excluded from the analysis as code of fluid lost.
Participants Participants were pre-hospital trauma victims attended to by emergency personnel within an hour of injury,
who had systolic blood pressure of 90m mmHg or less and were 16 years or older. 72% of participants had
sustained penetrating trauma.
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Interventions 1) 250 mL Dextran-70 in 7.5% NaCl (n=211).
2) 250 mL Ringer’s lactate, saline or plasmalyte. (n=211)
Allocated fluid was for initial pre-hospital resuscitation only.
Outcomes Deaths reported.
Notes Follow-up to hospital discharge or transfer.
Allocation concealment C – Inadequate
Study Mazher 1998
Methods Patients ’randomized’.
Blinding of care givers by use of pharmacy prepared solutions.
No loss to Follow-up.
Participants Patients undergoing elective coronary artery surgery.
Exclusions: age over 75, ejection fraction under 35%, creatinine over 135umol/L, ACE inhibitors.
Interventions 1) 5mL/kg polygeline (n=10).
2) 5mL/kg 7.2% saline (n=10).
Allocated fluid given post-op over one hour. All patients subsequently receive polygeline and red blood cells.
Outcomes Haemodynamic variables.
Death.
Notes Follow-up to discharge from intensive care.
Allocation concealment B – Unclear
Study McNulty 1993
Methods Randomised controlled trial. Method of allocation concealment not described.
Blinding not mentioned.
No loss to follow-up.
Participants Patients following elective cardiopulmonary bypass.
Interventions 1) 5% albumin and cell-saved blood (n=14).
2) Plasmalyte and cell-saved blood (n=14).
Allocated fluid used as part of fluid volume replacement.
Outcomes Deaths not reported.
Study was designed to look at the effect of protein infusion on the accuracy of a haematocrit measuring
device.
Notes Length of follow-up unspecified.
Allocation concealment B – Unclear
Study Metildi 1984
Methods Randomised controlled trial.
Blinding not mentioned.
No loss to follow-up.
Participants Participants were admissions to an intensive care and a trauma unit with adult respiratory distress syndrome
and established pulmonary failure. Included both trauma and non-trauma patients.
Interventions 1) 5% salt-poor albumin (n=20).
2) Ringer’s lactate (n=26).
Allocated fluid was used throughout resuscitation, and if an operation was required the allocated fluid was
used for volume replacement before and during the operation.
Outcomes Deaths reported.
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Haemodynamic variables.
Notes Follow-up to discharge.
Allocation concealment B – Unclear
Study Modig 1983
Methods Quasi-randomised controlled trial, allocation by admission date.
Blinding not mentioned.
No loss to follow-up.
Participants Participants were trauma admissions to an emergency department with a systolic blood pressure of less than
70mmHg. Age range was 20-58 years.
Interventions 1) Dextran-70 in Ringer’s lactate (n=12).
2) Ringer’s lactate. (n=11)
Allocated fluids were given as the initial resuscitation fluid on admission to the emergency department, and
continued as needed until after the 6th day when major reconstructive surgery was undertaken.
Outcomes Deaths reported.
Development of respiratory distress syndrome.
Notes Follow-up to definitive reconstructive surgery.
Allocation concealment C – Inadequate
Study Nagy 1993
Methods Randomised controlled trial, contact with author showed it was an open label study.
Blinding not mentioned.
No loss to follow-up.
Participants Participants were adult admissions to a trauma unit, with measurable systolic blood pressure less than 90
mmHg.
Interventions 1) Pentastarch in 0.9% NaCl (n=21).
2) Ringer’s lactate (n=20).
Allocatedfluidwas used throughout resuscitationwith the exception that colloid patients recieved amaximum
4L of pentastarch, after which Ringer’s lactate was given.
Outcomes Deaths were not reported.
Haemodynamic variables.
Notes Follow-up to discharge.
Allocation concealment C – Inadequate
Study Ngo 2001
Methods Randomised controlled trial, opaque envelopes containing only treatment pack number.
Participants 230 children with dengue shock syndrome.
Interventions 1) Dextran 70 (n=55).
2) 3% gelatine (n=56).
3) Lactated Ringer’s (n=55).
4) ’Normal’ saline (n=56).
Outcomes Initial pulse recovery time.
Occurrence of timing and subsequent episodes of shock.
Fall in haematocrit.
Volume of fluid administered till recovery.
Complications.
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And noted that there were no deaths in any group
Notes Follow-up period unclear.
Allocation concealment A – Adequate
Study Nielsen 1985
Methods Randomised controlled trial.
Method of allocation concealment not described.
Blinding not mentioned.
No loss to follow-up.
Participants 26 patients admitted for reconstructive surgery of the abdominal aorta.
Interventions 1) Whole blood, crystalloid plus 80g albumin on the day of the operation, and 20g per day for the next 3
days. Albumin given as 100mL 20% human albumin solution. (n=13)
2) Whole blood and crystalloid, type not specified. (n=13)
Outcomes Deaths not reported.
Author when contacted confirmed that there were no deaths in either group.
Notes Length of follow-up 4 days.
Allocation concealment B – Unclear
Study Pockaj 1994
Methods Randomised controlled trial, allocation concealment unclear.
Blinding not mentioned.
Loss to Follow-up 18/54 in colloid group, 13/53 in saline group.
Participants Participants required fluid resuscitation as a result of vascular leak syndrome associated with Interleukin-2
therapy for metastatic cancer.
Interventions 1) 250 mL boluses of 5% albumin in saline (n=36 reported).
2) 250 mL boluses of 0.9% normal saline. (n=40 reported)
Boluses guided by haemodynamic variables. Both groups also received 0.45% saline with 10mmol/L KCl.
Outcomes Deaths.
Toxic effects of chemotherapy.
Haemodynamic variables.
Notes
Allocation concealment B – Unclear
Study Prien 1990
Methods Randomised controlled trial.
Blinding not mentioned.
No loss to Follow-up.
Participants Participants were undergoing modified Whipple’s operation.
Interventions 1) 10% hydroxyethyl starch in 0.9% saline plus plasma protein fraction if requirements > 20mL/kg. (n=6)
2) 20% human albumin solution. (n=6)
3) Ringer’s lactate.
Allocated fluid was administered intra-operatively only.
Outcomes Deaths.
Intestinal oedema formation.
Notes Follow-up period was unspecifed.
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Allocation concealment B – Unclear
Study Rackow 1983
Methods Randomised controlled trial, allocation concealment unclear.
Blinding not mentioned.
No loss to follow-up.
Participants Participants were aged 54 to 97, and had any one of the following pre-determined indicators of shock: systolic
blood pressure of 90 mmHg or less, a cardiac index of less than 2.2 L./min.m2, a serum arterial lactate greater
than 18mg/dl and WP less than 15mmHg.
Interventions 1) 6% hydroxoethyl starch (n=9).
2) 5% albumin (n=9).
3) 0.9% saline. (n=8).
Allocated fluid was given as needed until the end of resuscitation.
Outcomes Deaths reported.
Fluid balance.
Notes Follow-up to discharge from hospital.
Allocation concealment B – Unclear
Study Rocha e Silva 1994
Methods Randomised controlled trial.
Participants Participants were admissions to the emergency room, with a systolic blood pressure of 90 mmHg or less and
were 16 years of age or older.
Interventions Colloid group received 6% dextran-70 in 7.5% NaCl; crystalloid group received Ringer’s lactate. Allocated
fluid was used for the first intravenous infusion only.
Outcomes Death was the main outcome measure, but the data are unpublished.
Notes Follow-up to 30 days. By April 1994, 125 patients had been entered into the study.
Allocation concealment B – Unclear
Study SAFE 2004
Methods Randomised controlled trial. Randomisation by minisation algorithm accessed through secure website
Participants Patients aged 18 years and above admitted to closed multidisciplinary intensive care units in 16 tertiary
hospitals in Australia over19-month period
Interventions 1) 4% albumin (Albumex, CSL) (n=3499).
2) Normal saline (n=3501).
Outcomes Death.
Pateints with new single or multiple-organ failure.
Mean number of days: in ICU, in hospital, on mechanical ventilation, on renal replacement therapy.
Notes Follow-up to 28 days.
Allocation concealment A – Adequate
Study Shah 1977
Methods Randomised controlled trial. Allocation by sealed envelope.
Blinding not mentioned.
No loss to follow-up.
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Participants Patients with severe, multiple trauma and a systolic blood pressure of less than 90mmHg. All patients were
adults and both sexes were included.
Interventions 1) 5% salt-poor albumin in Ringer’s lactate (n=9).
2) Ringer’s lactate (n=11).
Volume infused guided by physiological parameters.
Outcomes Death reported.
Haemodynamic variables.
Notes Length of follow-up not stated.
Allocation concealment B – Unclear
Study Shires 1983
Methods Patients ’assigned randomly’.
Blinding not mentioned.
No loss to follow-up.
Participants People undergoing aortic reconstruction surgery.
No exclusion criteria mentioned.
Interventions 1) Plasmanate (n=9).
2) Ringer’s lactate (n=9).
Allocated fluid used guided by haemodynamic variables until the first postoperative morning. All patients
then received 0.45% saline.
Outcomes Lung water.
Haemodynamic variables.
Death.
Notes Follow-up to two days post-op.
Allocation concealment B – Unclear
Study Sirieix 1999
Methods Patients ’randomly assigned’. Blinding not described.
Two patients excluded after randomisation due to arrhythmias on giving the fluid (both in hypertonic saline
group).
Participants Patients undergoing mitral valve repair.
Exclusions: LVEF<0.4, systolic PAP>50mmHg, coagulation disorders, creatinine>150mmoL/L, electrolyte
imbalance, diabetes, previous atrial fibrillation lasting > 1 year.
Interventions 1) 250mL 7.2% hypertonic saline, 6%HES (n=8).
2) 250mL 7.2% hypertonic saline (n=10).
3) 250mL 6% HES (n=8).
Fluid given over 15mins, I hour after admission to post-op intensive care
Outcomes Haemodynamic variables.
Deaths reported.
Side-effects (2 had severe hypotension in group 2 and 1 in group 1; arrhythmias in 1 patient in group 1, 3
in group 2 and 1 in group 3).
Notes Follow-up to discharge from hospital (all within 10 days)
Allocation concealment B – Unclear
Study Skillman 1975
Methods Randomised controlled trial, allocation concealment unclear.
Blinding not mentioned.
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No loss to Follow-up.
Participants Participants were undergoing elective abdominal reconstructive surgery.
Interventions 1) 25% salt-poor albumin 1g/kg and 5% albumin 1L. (n=7)
2) Ringer’s lactate.
Allocated fluid was given intra-operatively. All patients received crystalloids only for pre-loading before
surgery.
Outcomes Deaths were not reported.
Notes
Allocation concealment B – Unclear
Study Tollofsrud 1995
Methods Randomised controlled trial, allocation by sealed envelopes.
Blinding not mentioned.
No loss to follow-up.
Participants Participants were adult patients in need of volume replacement during and after coronary artery bypass
surgery.
Interventions 1) Haemaccel (n=10).
2) Dextran 70 (n=10).
3) Albumin 40 (n=10).
4) Ringer’s lactate (n=10).
Allocated fluid was used throughout resuscitation.
Outcomes Deaths reported.
Fluid balance.
Notes Follow-up to 48 hours.
Allocation concealment B – Unclear
Study Tollofsrud 1998
Methods Randomised controlled trial, allocation by sealed envelope. Described as double blind, no loss to follow-up
mentioned.
Participants Patients with three vessel coronary artery disease undergoing elective coronary artery surgery. Exclusions:
LVEF<0.4, ventricular aneurysm, significant arrhythmia, diabetes, renal failure, lung disease.
Interventions 1) 4mL/kg of 75mg/mL hypertonic saline in dextran 70 60mg/mL over 30 mins (n=10).
2) Same volume and rate of isotonic saline (n=10).
Fluid given just after surgery while still in operating theatre. Ringer’s lactate for additional fluid.
Outcomes Fluid balance.
Haemodynamic variables.
Deaths not reported.
Notes Follow-up to 48 hours.
Allocation concealment B – Unclear
Study Vassar 1990
Methods Randomised controlled trial, allocation concealment unclear.
Double blind study (solutions prepared in identical containers).
No loss to follow-up.
Participants Participants were emergency department admissions with trauma and a systolic blood pressure below
80mmHg and were 18 years or older.
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Pregnant women and people with preexisting cardiac, hepatic or renal disease were excluded.
Interventions 1) 6% dextran 70 in 7.5% saline. (n=23).
2) Ringer’s lactate (n=24).
Allocated fluids were given as the initial resuscitation in the emergency department. Additional isotonic
crystalloids (Ringer’s lactate) were given as needed.
Outcomes Deaths reported.
Haemodynamic variables.
Notes Follow-up to hospital discharge.
Allocation concealment B – Unclear
Study Vassar 1991
Methods Randomised controlled trial, allocation by randomised sequence of coded containers.
Double blind study.
No loss to follow-up.
Participants Participants were pre-hospital trauma cases undergoing helicoptor transport to an emergency centre, with a
systolic blood pressure of 100mmHg or less and were 18 years or older.
Exclusions: preexisting cardiac renal, hepatic or eurological disease. Peripheral oedema.
Interventions 1) 4.2% dextran 70 in 7.5% saline or 6% dextran 70 in 7.5% saline. (n=83)
2) Ringer’s lactate. (n=83)
Fluids were given as the initial resuscitation fluid in the pre-hospital setting. Supplemental isotonic fluids
were given at the discretion of the flight nurses.
Outcomes Deaths reported.
Haemodynamic variables
Notes Follow-up to discharge. Allocation was to 4.2% dextran-70; to 6% dextran-70; or to crystalloid; for the
calculation of the summary effect measure, the two dextran groups are combined.
Allocation concealment A – Adequate
Study Vassar 1993a
Methods Randomised controlled blind trial, allocation concealed by random sequence of identical containers.
Double blind study.
36 people excluded post randomisation as deemed not to have met eligibility criteria.
No loss to Follow-up.
Participants Participants, who were undergoing ambulance transport to an emergency centre, had systolic blood pressure
90 mmHg or less, and were 18 years or older.
Exclusions: asystolic, undergoing CPR, lack sinus complex on ECG, more than 2 hours after trauma,
pregnant, preexisting seizures, bleeding disorder, hepatic, cardiac or renal disease.
Interventions 1) 6% dextran 70 in 7.5% saline. (n=89)
2) 7.5% saline. (n=85)
3) 0.9% saline (n=84)
Participants received 250mL of the allocated fluid in the pre-hospital setting. Additional isotonic crystalloids
were given as needed.
Outcomes Deaths reported.
Haemodynamic variables.
Trauma scores.
Notes Follow-up was to discharge from hospital.
Allocation concealment A – Adequate
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Study Vassar 1993b
Methods Randomised controlled trial, allocation concealed by sequential use of coded identical containers.
Double blind study.
39/233 patients excluded as deemed not to meet eligibility criteria, unclear from which groups.
Participants Participants were pre-hospital trauma cases undergoing helicoptor transport to an emergency centre, had a
systolic blood pressure of 100mmHg or less and were 18 years or older.
Exclusions: asystolic, undergoing CPR, lack sinus complex on ECG, more than 2 hours after trauma,
pregnant, preexisting seizures, bleeding disorder, hepatic, cardiac or renal disease.
Interventions 1) 12% dextran70 in 7.5% saline. (n=49)
2) 6% dextran 70 in 7.5% saline. (n=50)
3) 7.5% saline. (n=50)
4) Ringer’s lactate. (n=45)
Participants received 250mL of the allocated fluid in the pre-hospital setting. Additional isotonic crystalloids
were given as needed.
Outcomes Deaths reported.
Haemodynamic variables.
Trauma scores and neurological outcome scores.
Notes Follow-up to hospital discharge.
Allocation concealment A – Adequate
Study Virgilio 1979
Methods Allocation ’by random number’.
Blinding not mentioned.
No loss to Follow-up.
Participants Participants were undergoing abdominal aortic surgery.
Interventions 1) 5% albumin. (n=15).
2) Ringer’s lactate (n=14).
Allocated fluid was used during operation for maintenence of pre-defined physiological parameters, and the
resuscitation was continued with the allocated fluid until the day following the operation. This was followed
by 5% dextrose in half-normal saline, with potassium chloride as needed.
Outcomes Deaths reported.
Notes Follow-up two and a half weeks
Allocation concealment B – Unclear
Study Wahba 1996
Methods Patients ’randomly allocated’.
Blinding not mentioned.
Two patients excluded as they required reoperation for bleeding.
Participants 22 adult patients in need of volume replacement following coronary artery bypass surgery.
Exclusions: abnormal left ventricular function, platelet active medication or heparin.
Interventions 1) Haemaccell (n=10).
2) Ringer’s lactate (n=10).
Allocated fluid was used from the time of admission to intensive care following operation, to the end of
resuscitation.
Outcomes Deaths reported.
Pulmonary oedema.
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Notes Follow-up to discharge.
Allocation concealment B – Unclear
Study Woittiez 1997
Methods Randomised controlled trial, allocation concealment by sealed opaque envelopes.
No information on blinding or loss to follow-up.
Participants 60 patients who had developed hypoalbuminaemia (<20g/l) after major surgery.
2 patients died after randomisation and before treatment started. They were excluded from the analysis.
Interventions 1) saline (500ml/24 hr) (n=16).
2) albumin 20% (300 ml/24h) (n=15).
3) HES 10% (500ml/24h) for 3 days (n=27).
Aim was to restore colloid osmotic pressure.
Outcomes Changes in fluid balance, serum albumin, COP and clinical signs of oedema were followed daily.
Death rates supplied by the author.
Notes Length of follow-up unspecified.
Allocation concealment B – Unclear
Study Wu 2001
Methods Randomised controlled trial. No details given of randmisation method.
Participants 41 adolescent or adult patients in emergency room suffering from shock.
Interventions 1) 4% modified fluid gelatin: succinated gelatin 40g/L, sodium chloride 7g/L, sodium hydroxide 1.36g/L
(n=18).
2) Lactated Ringer’s (n=16).
Outcomes Death
Haemodynamic variables.
Notes Not intention-to-treat: five patients who received blood transfusion and two who had surgery within the first
hour of resuscitation were dropped from the analysis.
Length of follow-up not clear.
Allocation concealment B – Unclear
Study Younes 1992
Methods Randomised ’in a double blind fashion’.
Blinding by use of similar bottles.
No loss to follow-up.
Participants Participants were emergency department admissions, who had a systolic blood pressure of less than 80mmHg
and were 19 years and older.
Exclusions: pregnant, preexisting cardiac or metabolic disease.
Interventions 1) 6% dextran 70 in 7.5% saline (n=35).
2) 7.5% saline (n=35).
3) 0.9% saline (n=35).
Allocated fluid was for initial bolus of 250mL, followed by isotonic crystalloids as needed.
Outcomes Deaths reported.
Fluid balance.
Notes Follow-up to discharge from hospital.
Allocation concealment B – Unclear
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Study Younes 1994
Methods Trial conducted in a ’double blind randomised fashion’.
Blinding by use of coded, identical containers.
Participants Participants were trauma admissions to the emergency room requiring treatment for haemorrhagic hypo-
volaemia; all were over 15 years old.
Exclusions: pregnant, cardiac or renal failure, cardiac arrest on arrival.
Interventions 1) 6% dextran 70 in 7.5% saline (n=101).
2) 0.9% saline. (n=111)
Allocated fluid was for the first intravenous infusion only.
Outcomes Deaths reported.
Complications.
Notes Follow-up period was 30 days.
Allocation concealment B – Unclear
Study Younes 1998
Methods Randomised controlled trial, allocation by sealed envelope. Blinding not mentioned, no apparent loss to
follow-up.
Participants Trauma patients with systolic blood pressure <90mmHg admitted to the emergency room, with no previous
treatment.
Interventions 1) 10% pentastarch (n=12).
2) 0.9% saline (n=11).
Fluid given in 250mL boluses until systolic blood pressure>100mmHg
Outcomes Deaths reported.
No complications reported in either group.
Notes Follow-up to 24 hours.
Allocation concealment B – Unclear
Study Zetterstrom 1981a
Methods The patients were randomly divided into two groups.
Allocation concealment was by sealed opaque envelopes (information supplied by author).
Blinding not mentioned.
No loss to follow-up.
Participants Adult patients undergoing elective major abdominal surgery.
Interventions 1) Standard volume replacement regimen (1L Dextran 70 then up to 4 units of RBC with electrolyte, then
whole blood or RBC with plasma; post-op patients were given crystalloids and whole blood) plus 20%
human albumin solution 100ml at end of operation, 200-300ml on same day, then 200ml on first post-op
day, then 100ml for next 3 days (n=15).
2) Standard volume replacement regimen as above (n=15).
Outcomes Deaths reported.
Haemodynamic variables.
Notes Length of follow-up unspecified.
Allocation concealment B – Unclear
Study Zetterstrom 1981b
Methods The patients were randomly divided into two groups.
Allocation concealment was by sealed opaque envelopes (information supplied by author).
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Blinding not mentioned.
No loss to follow-up.
Participants 18 patients who had undergone elective abdominal aortic surgery.
No exclusions mentioned.
Interventions 1) 5% human albumin solution (n=9).
2) Ringer’s lactate solution (n=9).
Administration guided by pulmonary arterial occlusion pressure.
Outcomes Deaths reported.
Haemodynamic variables.
Notes Follow-up to discharge from hospital.
Allocation concealment B – Unclear
COP = colloid osmotic pressure
HES = hydroxyethylstarch
LVEDP = left ventricular end diastolic pressure
LVEF = left ventricular ejection fraction
RBC = red blood cells
PAWP = pulmonary artery wedge pressure
PAP = pulmonary artery pressure
WP = wedge pressure
Characteristics of excluded studies
Study Reason for exclusion
Artru 1989 Intervention to control intracranial pressure not directed at fluid resuscitation.
Bocanegra 1966 This study contained two quasi-randomised comparisons of colloid with glucose and plasma/saline with saline. In
both studies, the control solution was only given IV if the patient was in coma or shock. It was therefore not a
reasonable comparison of colloid and crystalloid.
Boldt 1996 All groups received some colloid.
Bothner 1998 Participants were having minor elective surgery, therefore not considered to be critically ill.
Breheme 1993 Intervention directed at haemodilution, not at volume replacement.
Golub 1994 Albumin given solely as a nutritional supplement.
Goslinga 1992 Intervention directed at haemodilution, not volume replacement.
Greenhalgh 1995 Intervention directed at the maintenance of serum albumin levels, not for volume replacement.
Hauser 1980 Cross-over trial.
Lagonidis 1995 Intervention was pre-loading for coronary artery bypass sugery.
Marhofer 1999 Trial of fluid for preloading before spinal anaesthesia.
Nilsson 1980 Albumin given as a nutritional supplement.
Rehm 2001 Two colloids (albumin and hetastarch) compared.
Steinberg 1989 Cross-over trial.
Wilkes 2001 One group receveived saline plus hetastarch; the other received ’balanced’ fluid plus hetatstarch. Thus, each group
received both a colloid and a crystalloid. This conflicts with the purpose our review which compares patients who
had one of these with patients who had the other.
Woods 1993 This quasi-randomised trial looked at albumin supplementation in post operative patients, with the aim of main-
taining the serum albumin. Since the main aim of giving albumin was not to replace volume, the study was ex-
cluded.
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Characteristics of excluded studies (Continued )
A N A L Y S E S
Comparison 01. colloid vs crystalloid (add-on colloid)
Outcome title
No. of
studies
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01 deaths Relative Risk (Fixed) 95% CI Subtotals only
Comparison 02. colloid and hypertonic crystalloid vs isotonic crystalloid
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No. of
studies
No. of
participants Statistical method Effect size
01 deaths Relative Risk (Fixed) 95% CI Subtotals only
Comparison 03. colloid vs hypertonic crystalloid
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 deaths Relative Risk (Fixed) 95% CI Subtotals only
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Analysis 01.01. Comparison 01 colloid vs crystalloid (add-on colloid), Outcome 01 deaths
Review: Colloids versus crystalloids for fluid resuscitation in critically ill patients
Comparison: 01 colloid vs crystalloid (add-on colloid)
Outcome: 01 deaths
Study colloid crystalloid Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
01 albumin or PPF
x Boldt 1986 0/1 0/1 0.0 Not estimable
x Boldt 1993 0/15 0/15 0.0 Not estimable
Boutros 1979 0/7 2/17 0.2 0.45 [ 0.02, 8.34 ]
x Gallagher 1985 0/5 0/5 0.0 Not estimable
Goodwin 1983 11/40 3/39 0.4 3.58 [ 1.08, 11.85 ]
Grundmann 1982 1/14 0/6 0.1 1.40 [ 0.06, 30.23 ]
Jelenko 1978 1/7 1/5 0.2 0.71 [ 0.06, 8.90 ]
Lowe 1977 3/77 4/94 0.5 0.92 [ 0.21, 3.97 ]
Lucas 1978 7/27 0/27 0.1 15.00 [ 0.90, 250.24 ]
Metildi 1984 12/20 12/26 1.4 1.30 [ 0.75, 2.25 ]
x Prien 1990 0/6 0/6 0.0 Not estimable
Rackow 1983 6/9 6/8 0.8 0.89 [ 0.48, 1.64 ]
SAFE 2004 726/3473 729/3460 95.0 0.99 [ 0.91, 1.09 ]
Shah 1977 2/9 3/11 0.4 0.81 [ 0.17, 3.87 ]
x Shires 1983 0/9 0/9 0.0 Not estimable
Tollofsrud 1995 0/10 1/10 0.2 0.33 [ 0.02, 7.32 ]
Virgilio 1979 1/15 1/14 0.1 0.93 [ 0.06, 13.54 ]
Woittiez 1997 8/15 4/16 0.5 2.13 [ 0.81, 5.64 ]
Zetterstrom 1981a 0/15 1/15 0.2 0.33 [ 0.01, 7.58 ]
Zetterstrom 1981b 2/9 0/9 0.1 5.00 [ 0.27, 91.52 ]
Subtotal (95% CI) 3783 3793 100.0 1.02 [ 0.93, 1.11 ]
Total events: 780 (colloid), 767 (crystalloid)
Test for heterogeneity chi-square=13.88 df=14 p=0.46 I² =0.0%
Test for overall effect z=0.41 p=0.7
02 hydroxyethylstarch
x Boldt 1993 0/30 0/15 0.0 Not estimable
x Boldt 2001 0/50 0/25 0.0 Not estimable
0.01 0.1 1 10 100
favours colloid favours crystalloid (Continued . . . )
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(. . . Continued)
Study colloid crystalloid Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
x Dehne 2001 0/45 0/15 0.0 Not estimable
x Lang 2001 0/21 0/21 0.0 Not estimable
Nagy 1993 2/21 2/20 12.0 0.95 [ 0.15, 6.13 ]
Prien 1990 1/6 0/6 2.9 3.00 [ 0.15, 61.74 ]
Rackow 1983 5/9 6/8 37.2 0.74 [ 0.36, 1.50 ]
x Sirieix 1999 0/8 0/8 0.0 Not estimable
Woittiez 1997 13/27 4/16 29.5 1.93 [ 0.76, 4.90 ]
Younes 1998 2/12 3/11 18.4 0.61 [ 0.12, 3.00 ]
Subtotal (95% CI) 229 145 100.0 1.16 [ 0.68, 1.96 ]
Total events: 23 (colloid), 15 (crystalloid)
Test for heterogeneity chi-square=3.71 df=4 p=0.45 I² =0.0%
Test for overall effect z=0.55 p=0.6
03 modified gelatin
x Boldt 1993 0/15 0/15 0.0 Not estimable
x Boldt 2001 0/25 0/25 0.0 Not estimable
Evans 1996 1/11 2/14 27.3 0.64 [ 0.07, 6.14 ]
x Ngo 2001 0/56 0/111 0.0 Not estimable
Tollofsrud 1995 0/10 1/10 23.3 0.33 [ 0.02, 7.32 ]
x Wahba 1996 0/10 0/10 0.0 Not estimable
Wu 2001 2/18 3/16 49.4 0.59 [ 0.11, 3.11 ]
Subtotal (95% CI) 145 201 100.0 0.54 [ 0.16, 1.85 ]
Total events: 3 (colloid), 6 (crystalloid)
Test for heterogeneity chi-square=0.13 df=2 p=0.94 I² =0.0%
Test for overall effect z=0.98 p=0.3
04 dextran
Dawidson 1991 1/10 1/10 1.5 1.00 [ 0.07, 13.87 ]
Hall 1978 18/86 16/86 24.7 1.13 [ 0.62, 2.06 ]
Karanko 1987 0/14 1/18 2.0 0.42 [ 0.02, 9.64 ]
x Modig 1983 0/14 0/17 0.0 Not estimable
x Ngo 2001 0/55 0/111 0.0 Not estimable
Tollofsrud 1995 0/10 1/10 2.3 0.33 [ 0.02, 7.32 ]
Vassar 1993a 21/89 11/85 17.4 1.82 [ 0.94, 3.55 ]
Vassar 1993b 49/99 20/50 41.1 1.24 [ 0.83, 1.83 ]
Younes 1992 7/35 7/35 10.8 1.00 [ 0.39, 2.55 ]
0.01 0.1 1 10 100
favours colloid favours crystalloid (Continued . . . )
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(. . . Continued)
Study colloid crystalloid Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
Subtotal (95% CI) 412 422 100.0 1.24 [ 0.94, 1.65 ]
Total events: 96 (colloid), 57 (crystalloid)
Test for heterogeneity chi-square=2.76 df=6 p=0.84 I² =0.0%
Test for overall effect z=1.53 p=0.1
0.01 0.1 1 10 100
favours colloid favours crystalloid
Analysis 02.01. Comparison 02 colloid and hypertonic crystalloid vs isotonic crystalloid, Outcome 01 deaths
Review: Colloids versus crystalloids for fluid resuscitation in critically ill patients
Comparison: 02 colloid and hypertonic crystalloid vs isotonic crystalloid
Outcome: 01 deaths
Study Treatment Control Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
01 albumin or PPF
Jelenko 1978 1/7 2/7 100.0 0.50 [ 0.06, 4.33 ]
Subtotal (95% CI) 7 7 100.0 0.50 [ 0.06, 4.33 ]
Total events: 1 (Treatment), 2 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=0.63 p=0.5
02 hydroxyethylstarch
Subtotal (95% CI) 0 0 0.0 Not estimable
Total events: 0 (Treatment), 0 (Control)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
03 modified gelatin
Subtotal (95% CI) 0 0 0.0 Not estimable
Total events: 0 (Treatment), 0 (Control)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
04 dextran
Chavez-Negrete 1991 1/26 5/23 2.9 0.18 [ 0.02, 1.41 ]
Mattox 1991 35/211 42/211 22.6 0.83 [ 0.56, 1.25 ]
Vassar 1990 12/23 13/24 6.8 0.96 [ 0.56, 1.65 ]
Vassar 1991 30/83 34/83 18.3 0.88 [ 0.60, 1.30 ]
Vassar 1993a 21/89 14/84 7.7 1.42 [ 0.77, 2.60 ]
Vassar 1993b 49/99 23/45 17.0 0.97 [ 0.68, 1.37 ]
0.01 0.1 1 10 100 (Continued . . . )
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(. . . Continued)
Study Treatment Control Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
Younes 1992 7/35 8/35 4.3 0.88 [ 0.36, 2.15 ]
Younes 1994 27/101 40/111 20.5 0.74 [ 0.49, 1.11 ]
Subtotal (95% CI) 667 616 100.0 0.88 [ 0.74, 1.05 ]
Total events: 182 (Treatment), 179 (Control)
Test for heterogeneity chi-square=5.79 df=7 p=0.57 I² =0.0%
Test for overall effect z=1.41 p=0.2
0.01 0.1 1 10 100
Analysis 03.01. Comparison 03 colloid vs hypertonic crystalloid, Outcome 01 deaths
Review: Colloids versus crystalloids for fluid resuscitation in critically ill patients
Comparison: 03 colloid vs hypertonic crystalloid
Outcome: 01 deaths
Study Treatment Control Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
01 albumin or PPF
Bowser-Wallace 1986 3/19 0/19 100.0 7.00 [ 0.39, 126.92 ]
Subtotal (95% CI) 19 19 100.0 7.00 [ 0.39, 126.92 ]
Total events: 3 (Treatment), 0 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=1.32 p=0.2
02 hydroxyethylstarch
x Sirieix 1999 0/8 0/8 0.0 Not estimable
Subtotal (95% CI) 8 8 0.0 Not estimable
Total events: 0 (Treatment), 0 (Control)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
03 modified gelatin
x Mazher 1998 0/10 0/10 0.0 Not estimable
Subtotal (95% CI) 10 10 0.0 Not estimable
Total events: 0 (Treatment), 0 (Control)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
04 dextran
Subtotal (95% CI) 0 0 0.0 Not estimable
Total events: 0 (Treatment), 0 (Control)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
0.01 0.1 1 10 100
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